From the Guidelines
In relation to COVID-19 or respiratory therapy, IMS typically stands for Inspiratory Muscle Strength, which is a crucial factor in determining the severity of COVID-19 symptoms and outcomes, as evidenced by recent studies 1. The effects of COVID-19 on respiratory muscle performance have been extensively studied, and the findings suggest that SARS-CoV-2 infection can cause damage to the respiratory muscles, leading to persistent dyspnea in patients even after recovery from the viral infection 1. Some key points to consider in relation to IMS and COVID-19 include:
- The importance of screening for respiratory muscle weakness and providing interventions to improve respiratory muscle performance in patients with COVID-19 1
- The potential for mechanical ventilation to cause ventilator-induced diaphragm dysfunction (VIDD) and other adverse consequences for respiratory muscle performance 1
- The need for healthcare workers to understand the impact of COVID-19 on respiratory muscle performance and to take steps to mitigate these effects in patients 1 Overall, the evidence suggests that IMS is a critical factor in determining the severity of COVID-19 symptoms and outcomes, and that healthcare workers should prioritize interventions to improve respiratory muscle performance in patients with COVID-19.
From the Research
Inspiratory Muscle Strength (IMS) in Covid-19 or Respiratory Therapy
- Inspiratory Muscle Strength (IMS) is not explicitly defined in the provided studies as a specific term related to Covid-19 or respiratory therapy.
- However, the studies discuss various aspects of respiratory support and therapy in Covid-19 patients, including non-invasive ventilation (NIV), invasive mechanical ventilation (MV), and other modalities of respiratory support 2, 3, 4, 5, 6.
- The studies highlight the importance of understanding the pathophysiology of Covid-19-related respiratory failure and the need for personalized therapy in patients with Covid-19 4, 6.
- They also discuss the use of various techniques, such as continuous positive airway pressure (CPAP), high flow nasal oxygen therapy (HFNOT), and extracorporeal membrane oxygenation (ECMO), to support patients with Covid-19-related respiratory failure 2, 3, 5.
- The studies emphasize the need for careful monitoring of patients on respiratory support and the importance of timely intervention, including intubation and invasive mechanical ventilation, if needed 3, 5.